ACCPL — Accretion Pharmaceuticals Share Price
Last trade - 00:00- IN₹666.96m
- IN₹802.99m
- IN₹336.65m
- 24
- 41
- 38
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.91 | ||
| Price to Tang. Book | 4.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.98 | ||
| EV to EBITDA | 10.72 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 41.74% | ||
| Return on Equity | 44.48% | ||
| Operating Margin | 19.73% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | n/a | 222.92 | 293.84 | 336.65 | n/a | n/a | 22.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +31.52 | +3629.8 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 29th, 2023
- Public Since
- May 21st, 2025
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 11,116,000
- Address
- 29 Xcelon Ind Park 1, AHMEDABAD, 382213
- Web
- https://accretionpharma.com/
- Phone
- Auditors
- VS S B & Associates
Similar to ACCPL
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:03 UTC, shares in Accretion Pharmaceuticals are trading at IN₹60.00. This share price information is delayed by 15 minutes.
Shares in Accretion Pharmaceuticals last closed at IN₹60.00 and the price had moved by over the past 365 days. In terms of relative price strength the Accretion Pharmaceuticals share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreAccretion Pharmaceuticals does not currently pay a dividend.
Accretion Pharmaceuticals does not currently pay a dividend.
Accretion Pharmaceuticals does not currently pay a dividend.
To buy shares in Accretion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹60.00, shares in Accretion Pharmaceuticals had a market capitalisation of IN₹666.96m.
Here are the trading details for Accretion Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ACCPL
Based on an overall assessment of its quality, value and momentum Accretion Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accretion Pharmaceuticals. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹60.00, shares in Accretion Pharmaceuticals were trading -11.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Accretion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹60.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Accretion Pharmaceuticals' directors